Eptinezumab-jjmr (Vyepti)

Vyepti (eptinezumab‑jjmr) is covered only for the FDA‑approved preventive treatment of migraine in adults and excludes off‑label uses and concurrent use with other CGRP inhibitors. Approval (initial and renewal, each for 12 months) requires age ≥18, ≥4 migraine days/month, documented failure or intolerance to at least two standard prophylactic agents from different classes, dosing at 100 mg IV every 3 months, and renewal requires objective clinical benefit with supporting documentation of diagnosis, baseline migraine burden, prior trials, and infusion dates.

"Vyepti is indicated for the preventive treatment of migraine in adults."

Sign up to see full coverage criteria, indications, and limitations.